{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:09:25Z","timestamp":1780445365342,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T00:00:00Z","timestamp":1512000000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["16\/10\/12"],"award-info":[{"award-number":["16\/10\/12"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40273-017-0593-2","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T10:45:36Z","timestamp":1512038736000},"page":"387-398","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Ustekinumab for Treating Moderately to Severely Active Crohn\u2019s Disease after Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"36","author":[{"given":"Robert","family":"Hodgson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mousumi","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teumzghi","family":"Mebrahtu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerys","family":"Woolacott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,30]]},"reference":[{"key":"593_CR1","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the processes of technology appraisal. London: NICE; 2014. https:\/\/www.nice.org.uk\/article\/pmg19\/chapter\/foreword . Accessed 7 May 2017."},{"key":"593_CR2","unstructured":"Janssen. Ustekinumab for previously treated moderate to severe active Crohn\u2019s disease; submission to National Institute of Health and Clinical Excellence. Single technology appraisal (STA)."},{"key":"593_CR3","volume-title":"Evidence review group\u2019s report: ustekinumab for treating moderately to severely active CD after prior therapy [TA456]","author":"R Hodgson","year":"2017","unstructured":"Hodgson R, Biswas M, Mebrahtu T, Walton M, Harden M, Woolacott N. Evidence review group\u2019s report: ustekinumab for treating moderately to severely active CD after prior therapy [TA456]. York: University of York; 2017."},{"key":"593_CR4","unstructured":"National Institute for Health and Care Excellence (NICE). Ustekinumab for previously treated moderate to severe active Crohn\u2019s disease. Technology appraisal guidance [TA456] London: NICE; 2017. https:\/\/www.nice.org.uk\/guidance\/ta456 . Accessed 21 June 2017."},{"key":"593_CR5","unstructured":"National Institute for Health and Care Excellence (NICE). Crohn\u2019s disease overview. NICE Pathways. London: NICE; 2016. http:\/\/pathways.nice.org.uk\/pathways\/crohns-disease . Accessed 15 May 2017."},{"issue":"5","key":"593_CR6","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1080\/00365520601076124","volume":"42","author":"M Henriksen","year":"2007","unstructured":"Henriksen M, Jahnsen J, Lygren I, Aadland E, Schulz T, Vatn MH, et al. Clinical course in Crohn\u2019s disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol. 2007;42(5):602\u201310.","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"593_CR7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3109\/00365529509096316","volume":"30","author":"P Munkholm","year":"1995","unstructured":"Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn\u2019s disease patients. Scand J Gastroenterol. 1995;30(7):699\u2013706.","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"593_CR8","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.cgh.2007.09.002","volume":"5","author":"IC Solberg","year":"2007","unstructured":"Solberg IC, Vatn MH, Hoie O, Stray N, Sauar J, Jahnsen J, et al. Clinical course in Crohn\u2019s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430\u20138.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"593_CR9","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46\u201354.","journal-title":"Gastroenterology"},{"issue":"4","key":"593_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","volume":"12","author":"AN Ananthakrishnan","year":"2015","unstructured":"Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12(4):205\u201317.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"593_CR11","unstructured":"The IBD Standards Group. IBD Standards: Standards for the Healthcare of People who have Inflammatory Bowel Disease (IBD). British Society of Gastroenterology; 2013. https:\/\/www.crohnsandcolitis.org.uk\/improving-care-services\/health-services\/ibd-standards . Accessed 23 June 2017."},{"issue":"8","key":"593_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med"},{"key":"593_CR13","unstructured":"National Institute for Health and Care Excellence (NICE). Vedolizumab for treating moderately to severely active Crohn\u2019s disease after prior therapy. Technology appraisal guidance [TA352]. London: NICE; 2015. https:\/\/www.nice.org.uk\/guidance\/ta352 . Accessed 12 Dec 2015."},{"issue":"16","key":"593_CR14","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al. Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease. N Engl J Med. 2012;367(16):1519\u201328.","journal-title":"N Engl J Med"},{"key":"593_CR15","unstructured":"Committee for Medicinal Products for Human Use. Summary of opinion (Stelara\u00ae). London: European Medicines Agency; 2016. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion\/human\/000958\/WC500146594.pdf . Accessed 1 July 2017."},{"key":"593_CR16","unstructured":"National Institute for Health and Care Excellence (NICE). Ustekinumab for the treatment of adults with moderate to severe psoriasis. Technology appraisal guidance [TA180]. London: NICE; 2009. https:\/\/www.nice.org.uk\/guidance\/ta180 . Accessed 10 May 2017."},{"key":"593_CR17","unstructured":"National Institute for Health and Care Excellence (NICE). Ustekinumab for treating active psoriatic arthritis. Technology appraisal guidance [TA340]. London: NICE; 2015. https:\/\/www.nice.org.uk\/guidance\/ta340 . Accessed 10 May 2017."},{"issue":"Suppl 1","key":"593_CR18","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/MIB.0000000000000720","volume":"22","author":"W Sandborn","year":"2016","unstructured":"Sandborn W, Gasink C, Blank M, Lang Y, Johanns J, Gao LL, et al. O-001 A multicenter, double-blind, placebo-controlled phase 3 study of ustekinumab, a human IL-12\/23P40 mAB, in moderate-severe Crohn\u2019s disease refractory to anti-TNFalpha: UNITI-1. Inflamm Bowel Dis. 2016;22(Suppl 1):S1.","journal-title":"Inflamm Bowel Dis"},{"key":"593_CR19","unstructured":"Janssen Research and Development. A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of ustekinumab induction therapy in subjects with moderately to severely active Crohn\u2019s disease (UNITI 2); 13 October 2015."},{"issue":"20","key":"593_CR20","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","volume":"375","author":"BG Feagan","year":"2016","unstructured":"Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2016;375(20):1946\u201360.","journal-title":"N Engl J Med"},{"issue":"15","key":"593_CR21","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"593_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","volume":"130","author":"SB Hanauer","year":"2006","unstructured":"Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323\u201333.","journal-title":"Gastroenterology"},{"issue":"2","key":"593_CR23","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.crohns.2011.07.013","volume":"6","author":"M Watanabe","year":"2012","unstructured":"Watanabe M, Hibi T, Lomax KG, Paulson SK, Chao J, Alam MS, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn\u2019s disease. J Crohns Colitis. 2012;6(2):160\u201373.","journal-title":"J Crohns Colitis."},{"issue":"12","key":"593_CR24","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","volume":"146","author":"WJ Sandborn","year":"2007","unstructured":"Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146(12):829\u201338.","journal-title":"Ann Intern Med"},{"issue":"3","key":"593_CR25","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1053\/j.gastro.2014.05.008","volume":"147","author":"BE Sands","year":"2014","unstructured":"Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):627.","journal-title":"Gastroenterology."},{"issue":"1","key":"593_CR26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","volume":"132","author":"JF Colombel","year":"2007","unstructured":"Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial. Gastroenterology. 2007;132(1):52\u201365.","journal-title":"Gastroenterology"},{"key":"593_CR27","doi-asserted-by":"crossref","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet (London, England). 2002;359(9317):1541\u20139.","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"593_CR28","volume-title":"Evaluating complex interventions using multi-phase nested trial designs-Management of urinary incontinence across the primary\/secondary care interface. Controlled Clinical Trials","author":"K Abrams","year":"2003","unstructured":"Abrams K. Evaluating complex interventions using multi-phase nested trial designs-Management of urinary incontinence across the primary\/secondary care interface. Controlled Clinical Trials. New York: Elsevier Science Inc; 2003."},{"issue":"5","key":"593_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1586\/17474124.2015.1024657","volume":"9","author":"K Thorlund","year":"2015","unstructured":"Thorlund K, Druyts E, Toor K, Mills EJ. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol. 2015;9(5):693\u2013700.","journal-title":"Expert Rev Gastroenterol Hepatol."},{"issue":"3","key":"593_CR30","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2036.2009.04033.x","volume":"30","author":"K Bodger","year":"2009","unstructured":"Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn\u2019s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009;30(3):265\u201374.","journal-title":"Aliment Pharmacol Ther"},{"key":"593_CR31","unstructured":"Janssen Research and Development. A phase 3, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of ustekinumab maintenance therapy in subjects with moderately to severely active Crohn\u2019s disease (44-week Clinical Study Report). (EDMS-ERI-97847519, 1.0) Janssen Research and Development; 2015."},{"key":"593_CR32","unstructured":"National Institute for Health and Care Excellence (NICE). TA352. Vedolizumab for treating moderately to severely active Crohn\u2019s disease after prior therapy. Costing report. 2015 26 August 2015 [cited 2016 15 October]; Available from: https:\/\/www.nice.org.uk\/guidance\/ta352\/costing ."},{"key":"593_CR33","unstructured":"National Institute for Health and Care Excellence (NICE). Vedolizumab for treating moderately to severely active Crohn\u2019s disease after prior therapy. Costing report. London: NICE; 2015. https:\/\/www.nice.org.uk\/guidance\/ta352\/costing . Accessed 20 Oct 2016."},{"key":"593_CR34","unstructured":"Royal College of Physicians. National clinical audit of biological therapies: UK inflammatory bowel disease (IBD) audit. Royal College of Physicians; 2015. https:\/\/www.rcplondon.ac.uk\/projects\/outputs\/national-clinical-audit-report-biological-therapies-adult-report-2015 . Accessed 15 June 2017."},{"key":"593_CR35","doi-asserted-by":"crossref","unstructured":"Claxton K, Palmer S, Longworth L, Bojke L, Griffin S, Soares M, et al. A comprehensive algorithm for approval of health technologies with, without, or only in research: the key principles for informing coverage decisions. Value Health. 2016; 19(6):885\u201391.","DOI":"10.1016\/j.jval.2016.03.2003"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-017-0593-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0593-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0593-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,7]],"date-time":"2019-10-07T01:09:19Z","timestamp":1570410559000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-017-0593-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,30]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["593"],"URL":"https:\/\/doi.org\/10.1007\/s40273-017-0593-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,30]]},"assertion":[{"value":"30 November 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (project number 16\/10\/12). This summary of the ERG report was compiled after the Appraisal Committee\u2019s review and incorporates additional information and comment from the authors on the STA process and iterations of the NICE guidance not covered by the HTA report. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of NICE or the Department of Health. This work is Crown copyright (UK).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Robert Hodgson, Matthew Walton, Mousumi Biswas, Teumzghi Mebrahtu, and Nerys Woolacott have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}